Subcutaneous Ocrelizumab, Ofatumumab ' Reassuring ' in MS Subcutaneous Ocrelizumab, Ofatumumab ' Reassuring ' in MS

Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news